---
figid: PMC7425302__fonc-10-01290-g0001
figtitle: Cancer resistance to immunotherapy
organisms:
- Bacteroides fragilis
- Bacteroides thetaiotaomicron
- Homo sapiens
- Mus musculus
- gut metagenome
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC7425302
filename: fonc-10-01290-g0001.jpg
figlink: pmc/articles/PMC7425302/figure/F1/
number: F1
caption: 'Mechanisms of cancer resistance to immunotherapy. Key mechanisms of cancer
  resistance to immunotherapy are briefly described in the figure, including: (I)
  Tumor-intrinsic factors: (i) alteration of antitumor immune response pathways: (1)
  aberrant expression of tumor antigens and changes in immunogenicity (e.g., TAA,
  TSA, antigenic drift, ER stress and autophagy, genes involved in mitochondrial metabolism);
  (2) alterations in the antigen presentation pathways [e.g., proteasome, transporters,
  MHC (loss of HLA expression, β2-M mutations leading to loss of HLA)]; (ii) alteration
  of signaling pathways (e.g., interferon γ and its associated-signaling pathway);
  (iii) forming immunosuppressive microenvironment: (1) secreting inhibitory molecules
  (e.g., exosome PD-L1, PD-L1 variant fragment); (2) functional gene mutations [e.g.,
  Wnt/β-catenin signaling, PTEN/PI3K (phosphatase and tensin homolog/phosphatidylinositol
  3-kinase) signaling, CDK4-CDK6 signaling, MAPK signaling, EGFR, KRAS, STK11, PAK4];
  (3) altering metabolism in TME [e.g., hypoxic, expression of IDO, LXR, CD38/adenosine,
  CD73]; (II) factors of tumor local microenvironment: (i) immunosuppressive cells/molecules:
  immunosuppressive cells [e.g., MDSCs, Tregs, TAM]; activation of coinhibitory receptors
  (e.g., PD-L1, CTLA-4, TIM-3, TIGHT); inhibition of costimulatory receptor (e.g.,
  CD28); (ii) abnormal neovascularization; (III) host-related factors: (i) gender;
  (ii) age; (iii) distribution of body fat; (iv) gut microbiome.'
papertitle: Mechanisms of Cancer Resistance to Immunotherapy.
reftext: Rilan Bai, et al. Front Oncol. 2020;10:1290.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8020077
figid_alias: PMC7425302__F1
figtype: Figure
redirect_from: /figures/PMC7425302__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7425302__fonc-10-01290-g0001.html
  '@type': Dataset
  description: 'Mechanisms of cancer resistance to immunotherapy. Key mechanisms of
    cancer resistance to immunotherapy are briefly described in the figure, including:
    (I) Tumor-intrinsic factors: (i) alteration of antitumor immune response pathways:
    (1) aberrant expression of tumor antigens and changes in immunogenicity (e.g.,
    TAA, TSA, antigenic drift, ER stress and autophagy, genes involved in mitochondrial
    metabolism); (2) alterations in the antigen presentation pathways [e.g., proteasome,
    transporters, MHC (loss of HLA expression, β2-M mutations leading to loss of HLA)];
    (ii) alteration of signaling pathways (e.g., interferon γ and its associated-signaling
    pathway); (iii) forming immunosuppressive microenvironment: (1) secreting inhibitory
    molecules (e.g., exosome PD-L1, PD-L1 variant fragment); (2) functional gene mutations
    [e.g., Wnt/β-catenin signaling, PTEN/PI3K (phosphatase and tensin homolog/phosphatidylinositol
    3-kinase) signaling, CDK4-CDK6 signaling, MAPK signaling, EGFR, KRAS, STK11, PAK4];
    (3) altering metabolism in TME [e.g., hypoxic, expression of IDO, LXR, CD38/adenosine,
    CD73]; (II) factors of tumor local microenvironment: (i) immunosuppressive cells/molecules:
    immunosuppressive cells [e.g., MDSCs, Tregs, TAM]; activation of coinhibitory
    receptors (e.g., PD-L1, CTLA-4, TIM-3, TIGHT); inhibition of costimulatory receptor
    (e.g., CD28); (ii) abnormal neovascularization; (III) host-related factors: (i)
    gender; (ii) age; (iii) distribution of body fat; (iv) gut microbiome.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Renbp
  - Cd36
  - Cpe
  - Gusb
  - Cd80
  - Apc
  - Ctla4
  - Trav6-3
  - Pdcd1
  - Loca1
  - Ifng
  - B2m
  - Cd274
  - Ifngr1
  - Ifngr2
  - Pd
  - Havcr2
  - Tgfb1
  - Ltbp1
  - Csf1
  - CD36
  - FAT1
  - HLA-C
  - CD80
  - APC
  - PROC
  - CTLA4
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - IFNG
  - B2M
  - CD274
  - IFNGR1
  - IFNGR2
  - TAM
  - STIM1
  - HAVCR2
  - TGFB1
  - TGFB2
  - TGFB3
  - CSF1
  - ft
  - kug
  - faf
  - Mhc
  - zip
  - cd
  - as
  - Apc2
  - Axn
  - Fs(3)Apc
  - Tcr
  - pd
  - dc
  - PolG1
  - pyd
  - dpp
  - gbb
  - put
  - mav
  - TCR
  - TAM
  - tumor
---
